<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5503">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01126671</url>
  </required_header>
  <id_info>
    <org_study_id>08-06-0271</org_study_id>
    <nct_id>NCT01126671</nct_id>
  </id_info>
  <brief_title>Vitamin D Supplementation in Healthy Adolescents</brief_title>
  <official_title>Clinical Trial of Vitamin D Supplementation in Healthy Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Boston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital Boston</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This double blind, randomized controlled trial compares two supplemental doses of vitamin D
      in health adolescents.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vitamin D deficiency is a common problem. Currently, data do not support a recommended
      vitamin D supplementation dose for health adolescents to maintain normal vitamin D levels.
      This double blind, randomized controlled 12 week trial compares the use of two supplemental
      doses of vitamin D in this population.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Baseline 25OHD Levels</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>25OHD will be drawn at baseline prior to starting vitamin D supplementation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Follow-up 25OHD Levels</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>After 11weeks of treatment, repeat 25OHD levels will be drawn to assess subject response to vitamin D supplementation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Baseline Assessment of Bone Markers</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Bone specific alkaline phosphatase, CTx, and osteocalcin will be assessed at baseline prior to subjects starting vitamin D supplementation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Bone Markers at Follow-up</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>After 11 weeks of vitamin D supplementation bone specific alkaline phosphatase, osteocalcin, and CTx will be repeated to see response to therapy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Vitamin D Supplementation</condition>
  <arm_group>
    <arm_group_label>Low Dose Vitamin D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects are randomized to one of two supplemental vitamin D arms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose Vitamin D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects are randomized to one of two supplemental vitamin D treatment arms.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Supplemental Vitamin D</intervention_name>
    <description>Two doses of daily supplemental vitamin D taken for 11 weeks.</description>
    <arm_group_label>Low Dose Vitamin D</arm_group_label>
    <arm_group_label>High Dose Vitamin D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  11-18yo

          -  healthy

        Exclusion Criteria:

          -  chronic disease

          -  use of medication known to effect bone or vitamin D metabolism

          -  abnormal vitamin D or calcium at screening

          -  pregnant

          -  BMI&lt;5% or &gt;95%
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melissa Putman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Childrens Hospital, Boston</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sarah Pitts, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Childrens Hospital, Boston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 8, 2013</lastchanged_date>
  <firstreceived_date>May 18, 2010</firstreceived_date>
  <firstreceived_results_date>March 8, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital Boston</investigator_affiliation>
    <investigator_full_name>Sarah Pitts</investigator_full_name>
    <investigator_title>Attending Physician</investigator_title>
  </responsible_party>
  <keyword>vitamin D</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from the Boston Childrenâ€™s Hospital (BCH) Adolescent Medicine Outpatient Program and from the community via flyers, internet postings, and newspaper advertisements. Enrollment began September 1, 2008 and ended March 18, 2011.</recruitment_details>
      <pre_assignment_details>Healthy adolescents, ages 11-19 years, were eligible if clinically healthy, likely to comply with treatment, and not vitamin D deficient.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Low Dose Vitamin D</title>
          <description>Subjects in this arm of the study took 200 IU vit D3 daily.</description>
        </group>
        <group group_id="P2">
          <title>High Dose Vitamin D</title>
          <description>Subjects in this arm of the study took 1000 IU vit D3 daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Low Dose Vitamin D</title>
          <description>Subjects in this arm of the study took 200 IU vit D3 daily.</description>
        </group>
        <group group_id="B2">
          <title>High Dose Vitamin D</title>
          <description>Subjects in this arm of the study took 1000 IU vit D3 daily.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
                <measurement group_id="B2" value="29"/>
                <measurement group_id="B3" value="54"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="24"/>
                <measurement group_id="B2" value="26"/>
                <measurement group_id="B3" value="50"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="4"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="16.1" spread="2.2"/>
                <measurement group_id="B2" value="16.1" spread="2.2"/>
                <measurement group_id="B3" value="16.1" spread="2.2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="21"/>
                <measurement group_id="B2" value="18"/>
                <measurement group_id="B3" value="39"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
                <measurement group_id="B2" value="11"/>
                <measurement group_id="B3" value="15"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
                <measurement group_id="B2" value="29"/>
                <measurement group_id="B3" value="54"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Baseline 25OHD Levels</title>
        <description>25OHD will be drawn at baseline prior to starting vitamin D supplementation.</description>
        <time_frame>Baseline</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Vitamin D</title>
            <description>Subjects in this arm of the study took 200 IU vit D3 daily.</description>
          </group>
          <group group_id="O2">
            <title>High Dose Vitamin D</title>
            <description>Subjects in this arm of the study took 1000 IU vit D3 daily.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="29"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Baseline 25OHD Levels</title>
            <description>25OHD will be drawn at baseline prior to starting vitamin D supplementation.</description>
            <units>ng/ml</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28.1" spread="6.2"/>
                  <measurement group_id="O2" value="29" spread="7.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Follow-up 25OHD Levels</title>
        <description>After 11weeks of treatment, repeat 25OHD levels will be drawn to assess subject response to vitamin D supplementation.</description>
        <time_frame>12 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Vitamin D</title>
            <description>Subjects in this arm of the study took 200 IU vit D3 daily.</description>
          </group>
          <group group_id="O2">
            <title>High Dose Vitamin D</title>
            <description>Subjects in this arm of the study took 1000 IU vit D3 daily.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="29"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Follow-up 25OHD Levels</title>
            <description>After 11weeks of treatment, repeat 25OHD levels will be drawn to assess subject response to vitamin D supplementation.</description>
            <units>ng/ml</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28.9" spread="7"/>
                  <measurement group_id="O2" value="30.1" spread="6.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Assessment of Bone Markers</title>
        <description>Bone specific alkaline phosphatase, CTx, and osteocalcin will be assessed at baseline prior to subjects starting vitamin D supplementation</description>
        <time_frame>Baseline</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Bone Markers at Follow-up</title>
        <description>After 11 weeks of vitamin D supplementation bone specific alkaline phosphatase, osteocalcin, and CTx will be repeated to see response to therapy.</description>
        <time_frame>12 weeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Low Dose Vitamin D</title>
          <description>Subjects in this arm of the study took 200 IU vit D3 daily.</description>
        </group>
        <group group_id="E2">
          <title>High Dose Vitamin D</title>
          <description>Subjects in this arm of the study took 1000 IU vit D3 daily.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Sarah Pitts</name_or_title>
      <organization>Boston Children's Hospital</organization>
      <phone>617-355-3732</phone>
      <email>sarah.pitts@childrens.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
